SCHEMBL6465400

SCHEMBL6465400

Cc1cc(NC2CCC(NC(=O)c3cccc(OC(F)(F)F)c3)CC2)nc2ccccc12

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.51
LMNA P02545 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
MCHR1 Q99705 13/20 0.51
ADRA2A P08913 9/20 0.51
TAS1R3 Q7RTX0 1/20 0.49
TAS1R1 Q7RTX1 1/20 0.49
TAS1R2 Q8TE23 1/20 0.49
NPC1 O15118 1/20 0.49
PDE4B Q07343 1/20 0.47
PDE4D Q08499 1/20 0.47
HPGDS O60760 1/20 0.46
PKM P14618 1/20 0.45
HTR1A P08908 1/20 0.45
ADRA1A P35348 1/20 0.45
HRH1 P35367 1/20 0.45
HTR2B P41595 1/20 0.45
NPY5R Q15761 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6465392 1.00 KDM4E (0.51) KDM4ELMNASMN1; SMN2MCHR1ADRA2A
Hydrochloric Acid SCHEMBL6457484 0.99 MCHR1 (0.50) KDM4ELMNASMN1; SMN2MCHR1ADRA2A
Hydrochloric Acid SCHEMBL6457477 0.99 MCHR1 (0.50) KDM4ELMNASMN1; SMN2MCHR1ADRA2A
SCHEMBL6456233 0.92 MCHR1 (0.58) KDM4ELMNASMN1; SMN2MCHR1ADRA2A
SCHEMBL6456235 0.92 MCHR1 (0.58) KDM4ELMNASMN1; SMN2MCHR1ADRA2A
SCHEMBL6459746 0.89 MCHR1 (0.57) KDM4ELMNASMN1; SMN2MCHR1ADRA2A
SCHEMBL6459737 0.89 MCHR1 (0.57) KDM4ELMNASMN1; SMN2MCHR1ADRA2A
SCHEMBL6457452 0.89 MCHR1 (0.55) MCHR1ADRA2ATAS1R3TAS1R1TAS1R2
SCHEMBL6457460 0.89 MCHR1 (0.55) MCHR1ADRA2ATAS1R3TAS1R1TAS1R2
Hydrochloric Acid SCHEMBL6458068 0.88 MCHR1 (0.56) KDM4ELMNASMN1; SMN2MCHR1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US claimed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO claimed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP claimed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-1464335-A2 Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist Taisho Pharmaceutical Co. Ltd. (JP) 2004-10-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 KDM4E 1190/4885LMNA 3391/4885SMN1; SMN2 1477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.